CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Y-mAbs Therapeutics, Inc.

YMAB
$391MSmall Cap

Next catalyst

Phase 2December 2026

Hu3F8 With GM-CSF

Neuroblastoma

Get an email about YMAB's next catalysts

Track Y-mAbs Therapeutics (YMAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

Hu3F8 With GM-CSF Phase 2 Est. Readout

December 2026~Hu3F8 With GM-CSF186

Estimated primary completion for Hu3F8 With GM-CSF trial (NCT01757626) in Neuroblastoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

humanized anti-GD2 antibody Phase 2 Est. Readout

July 2027~humanized anti-GD2 antibody46

Estimated primary completion for humanized anti-GD2 antibody trial (NCT02502786) in Recurrent Osteosarcoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

131 I-omburtamab Phase 2 Est. Readout

July 2027~131 I-omburtamab31

Estimated primary completion for 131 I-omburtamab trial (NCT04022213) in Desmoplastic Small Round Cell Tumor. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaPRINCETON

Frequently asked questions

What is in Y-mAbs Therapeutics, Inc.'s drug pipeline?→

CatalystAlert tracks 12 drug candidates in Y-mAbs Therapeutics, Inc.'s (YMAB) pipeline across Phase 2. Its lead program is 131 I-omburtamab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Y-mAbs Therapeutics, Inc.'s next FDA catalyst?→

Y-mAbs Therapeutics, Inc.'s (YMAB) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track YMAB biotech catalysts?→

Add YMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Y-mAbs Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply